Maxim Group initiated coverage of Trxade Group with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $4.50 | Buy | EF Hutton |
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. ("Scienture Holdings"), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024. About TRxADE TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC ("IPS"), whi